PL2081937T3 - Triazolopirydazynowe modulatory kinaz białkowych - Google Patents

Triazolopirydazynowe modulatory kinaz białkowych

Info

Publication number
PL2081937T3
PL2081937T3 PL07854193T PL07854193T PL2081937T3 PL 2081937 T3 PL2081937 T3 PL 2081937T3 PL 07854193 T PL07854193 T PL 07854193T PL 07854193 T PL07854193 T PL 07854193T PL 2081937 T3 PL2081937 T3 PL 2081937T3
Authority
PL
Poland
Prior art keywords
triazolopyridazine
protein kinase
kinase modulators
modulators
protein
Prior art date
Application number
PL07854193T
Other languages
English (en)
Inventor
Christopher Ronald Smith
Pierre-Yves Bounaud
Elizabeth Anne Jefferson
Patrick S Lee
Eduardo Torres
Original Assignee
Sgx Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sgx Pharmaceuticals Inc filed Critical Sgx Pharmaceuticals Inc
Publication of PL2081937T3 publication Critical patent/PL2081937T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
PL07854193T 2006-10-23 2007-10-18 Triazolopirydazynowe modulatory kinaz białkowych PL2081937T3 (pl)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US86255206P 2006-10-23 2006-10-23
US87138406P 2006-12-21 2006-12-21
US91375207P 2007-04-24 2007-04-24
US95283307P 2007-07-30 2007-07-30
EP07854193A EP2081937B1 (en) 2006-10-23 2007-10-18 Triazolopyridazine protein kinase modulators
PCT/US2007/081832 WO2008051805A2 (en) 2006-10-23 2007-10-18 Triazolo-pyridazine protein kinase modulators

Publications (1)

Publication Number Publication Date
PL2081937T3 true PL2081937T3 (pl) 2013-01-31

Family

ID=39031065

Family Applications (1)

Application Number Title Priority Date Filing Date
PL07854193T PL2081937T3 (pl) 2006-10-23 2007-10-18 Triazolopirydazynowe modulatory kinaz białkowych

Country Status (16)

Country Link
US (1) US8071581B2 (pl)
EP (1) EP2081937B1 (pl)
JP (1) JP2010507577A (pl)
KR (1) KR101083177B1 (pl)
AU (1) AU2007309237B2 (pl)
BR (1) BRPI0717317A2 (pl)
CA (1) CA2667453A1 (pl)
DK (1) DK2081937T3 (pl)
EA (1) EA016527B1 (pl)
ES (1) ES2393132T3 (pl)
MX (1) MX2009004060A (pl)
PE (1) PE20081256A1 (pl)
PL (1) PL2081937T3 (pl)
PT (1) PT2081937E (pl)
TW (1) TW200833692A (pl)
WO (1) WO2008051805A2 (pl)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7645789B2 (en) 2006-04-07 2010-01-12 Vertex Pharmaceuticals Incorporated Indole derivatives as CFTR modulators
IN2014KN02423A (pl) 2006-04-07 2015-05-01 Vertex Pharma
US10022352B2 (en) 2006-04-07 2018-07-17 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
USRE50453E1 (en) 2006-04-07 2025-06-10 Vertex Pharmaceuticals Incorporated Indole derivatives as CFTR modulators
US8217177B2 (en) * 2006-07-14 2012-07-10 Amgen Inc. Fused heterocyclic derivatives and methods of use
PE20121506A1 (es) 2006-07-14 2012-11-26 Amgen Inc Compuestos triazolopiridinas como inhibidores de c-met
US8198448B2 (en) 2006-07-14 2012-06-12 Amgen Inc. Fused heterocyclic derivatives and methods of use
US7683060B2 (en) 2006-08-07 2010-03-23 Incyte Corporation Triazolotriazines as kinase inhibitors
US8563573B2 (en) 2007-11-02 2013-10-22 Vertex Pharmaceuticals Incorporated Azaindole derivatives as CFTR modulators
CA2669991C (en) 2006-11-22 2016-01-26 Incyte Corporation Imidazotriazines and imidazopyrimidines as kinase inhibitors
WO2009106577A1 (en) 2008-02-28 2009-09-03 Novartis Ag Imidazo [1,2-b] pyridazine derivatives for the treatment of c-met tyrosine kinase mediated disease
HUE034716T2 (hu) 2008-05-21 2018-02-28 Incyte Holdings Corp 2-Fluor-N-metil-4-[7-(kinolin-6-il-metil)-imidazo[1,2-b][1,2,4]triazin-2-il]benzamid sói és eljárások ezek elõállítására
DE102008028905A1 (de) 2008-06-18 2009-12-24 Merck Patent Gmbh 3-(3-Pyrimidin-2-yl-benzyl)-[1,2,4]triazolo[4,3-b]pyridazinderivate
DE102008037790A1 (de) 2008-08-14 2010-02-18 Merck Patent Gmbh Bicyclische Triazolderivate
DE102008038222A1 (de) 2008-08-18 2010-02-25 Merck Patent Gmbh Indazol-5-carbonsäurehydrazid-derivate
DE102008038220A1 (de) 2008-08-18 2010-02-25 Merck Patent Gmbh Oxadiazolderivate
DE102008038221A1 (de) 2008-08-18 2010-02-25 Merck Patent Gmbh 7-Azaindolderivate
JP2012509342A (ja) * 2008-11-20 2012-04-19 オーエスアイ・フアーマスーテイカルズ・インコーポレーテツド 置換ピロロ[2,3−b]−ピリジンおよび−ピラジン
CA2744563A1 (en) * 2008-12-12 2010-06-17 Ariad Pharmaceuticals, Inc. Azaindole derivatives as kinase inhibitors
DE102008063667A1 (de) 2008-12-18 2010-07-01 Merck Patent Gmbh 3-(3-Pyrimidin-2-yl-benzyl)-°[1,2,4]triazolo[4,3-b]pyrimidin-derivate
DE102008062825A1 (de) 2008-12-23 2010-06-24 Merck Patent Gmbh 3-(3-Pyrimidin-2-yl-benzyl)-[1,2,4]triazolo [4,3-b]pyridazin-derivate
ES2427917T3 (es) * 2009-02-10 2013-11-04 Astrazeneca Ab Derivados de triazolo [4,3-b] piridazina y sus usos para el cáncer de próstata
JP2012519731A (ja) * 2009-03-09 2012-08-30 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア ニコチン受容体およびgabaa受容体のアロステリックモジュレーターとしての置換複素環およびそれらの使用
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
BR112012003262A8 (pt) 2009-08-12 2016-05-17 Novartis Ag compostos de hidrazona heterocíclica e seus usos para tratar câncer e inflamação
EA201200318A1 (ru) 2009-08-20 2012-09-28 Новартис Аг Гетероциклические оксимы
US8987269B2 (en) * 2009-12-31 2015-03-24 Hutchison Medipharma Limited Certain triazolopyridines and triazolopyrazines, compositions thereof and methods of use therefor
CN102812027B (zh) 2010-02-03 2015-01-07 因西特公司 作为C-MET抑制剂的咪唑并[1,2-b][1,2,4]三嗪
US8802868B2 (en) 2010-03-25 2014-08-12 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
NZ734535A (en) * 2010-04-22 2019-05-31 Vertex Pharma Process of producing cycloalkylcarboxamido-indole compounds
AR081039A1 (es) 2010-05-14 2012-05-30 Osi Pharmaceuticals Llc Inhibidores biciclicos fusionados de quinasa
JP2013526570A (ja) 2010-05-14 2013-06-24 オーエスアイ・ファーマシューティカルズ,エルエルシー 縮合二環式キナーゼ阻害剤
NZ703111A (en) 2010-05-17 2016-07-29 Incozen Therapeutics Pvt Ltd Novel 3,5-disubstitued-3h-imidazo[4,5-b]pyridine and 3,5- disubstitued -3h-[1,2,3]triazolo[4,5-b] pyridine compounds as modulators of protein kinases
CN102985420B (zh) * 2010-06-01 2017-07-04 安吉翁生物医药有限公司 细胞色素p450抑制剂及其用途
US10414760B2 (en) 2016-11-29 2019-09-17 Angion Biomedica Corp. Cytochrome P450 inhibitors and uses thereof
AR085183A1 (es) 2010-07-30 2013-09-18 Lilly Co Eli Compuesto 6-(1-metil-1h-pirazol-4-il)-3-(2-metil-2h-indazol-5-iltio)-[1,2,4]triazol[4,3-b]piridazina, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para tratar cancer
US20130324526A1 (en) 2011-02-10 2013-12-05 Novartis Ag [1,2,4] triazolo [4,3-b] pyridazine compounds as inhibitors of the c-met tyrosine kinase
EP2710003A1 (en) 2011-05-16 2014-03-26 OSI Pharmaceuticals, LLC Fused bicyclic kinase inhibitors
JP5957526B2 (ja) 2011-09-15 2016-07-27 ノバルティス アーゲー チロシンキナーゼとしての6−置換3−(キノリン−6−イルチオ)−[1,2,4]トリアゾロ[4,3−a]ピラジン
EP2760866B1 (en) 2011-09-27 2017-12-13 Genfit Derivatives of 6-substituted triazolopyridazines as rev-erb agonists
KR101869534B1 (ko) * 2012-03-05 2018-06-20 한국화학연구원 신규한 트리아졸로 피리다진 유도체 및 그의 용도
WO2013144737A2 (en) 2012-03-30 2013-10-03 Rhizen Pharmaceuticals Sa Novel 3,5-disubstitued-3h-imidazo[4,5-b]pyridine and 3,5- disubstitued -3h-[1,2,3]triazolo[4,5-b] pyridine compounds as modulators of c-met protein kinases
AR092857A1 (es) 2012-07-16 2015-05-06 Vertex Pharma Composiciones farmaceuticas de (r)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-il)-n-(1-(2,3-dihidroxipropil)-6-fluoro-2-(1-hidroxi-2-metilpropan-2-il)-1h-indol-5-il)ciclopropancarboxamida y administracion de las mismas
CN103122000B (zh) 2012-09-03 2013-12-25 中美冠科生物技术(太仓)有限公司 用作抗肿瘤药物的高选择性的c-Met激酶抑制剂
KR20150070348A (ko) 2012-10-16 2015-06-24 얀센 파마슈티카 엔.브이. RoRγt의 헤테로아릴 결합 퀴놀리닐 조절제
CA2888485C (en) 2012-10-16 2021-01-26 Janssen Pharmaceutica Nv Phenyl linked quinolinyl modulators of ror.gamma.t
EA026415B1 (ru) 2012-10-16 2017-04-28 Янссен Фармацевтика Нв Связанные с метиленом хинолиниловые модуляторы ror-гамма-t
WO2014133526A1 (en) 2013-02-28 2014-09-04 Empire Technology Development Llc Colored pigment particles for electrophoretic displays
CA2897618A1 (en) * 2013-03-13 2014-09-18 F. Hoffmann-La Roche Ag Process for making benzoxazepin compounds
US20140303121A1 (en) 2013-03-15 2014-10-09 Plexxikon Inc. Heterocyclic compounds and uses thereof
PT2970265T (pt) 2013-03-15 2018-10-23 Plexxikon Inc Compostos heterocíclicos e suas utilizações
US9221804B2 (en) 2013-10-15 2015-12-29 Janssen Pharmaceutica Nv Secondary alcohol quinolinyl modulators of RORγt
KR20160070133A (ko) 2013-10-15 2016-06-17 얀센 파마슈티카 엔.브이. RORyt의 알킬 결합 퀴놀리닐 조절제
US10555941B2 (en) 2013-10-15 2020-02-11 Janssen Pharmaceutica Nv Alkyl linked quinolinyl modulators of RORγt
US9328095B2 (en) 2013-10-15 2016-05-03 Janssen Pharmaceutica Nv Heteroaryl linked quinolinyl modulators of RORgammat
US9403816B2 (en) 2013-10-15 2016-08-02 Janssen Pharmaceutica Nv Phenyl linked quinolinyl modulators of RORγt
US9284308B2 (en) 2013-10-15 2016-03-15 Janssen Pharmaceutica Nv Methylene linked quinolinyl modulators of RORγt
WO2015057626A1 (en) 2013-10-15 2015-04-23 Janssen Pharmaceutica Nv QUINOLINYL MODULATORS OF RORyT
GB201321745D0 (en) * 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
WO2015134854A2 (en) * 2014-03-06 2015-09-11 Oyagen, Inc. Small molecule vif dimerization antagonists as anti-hiv agents and for use as hiv/aids therapeutics
HUE055369T2 (hu) 2014-04-15 2021-11-29 Vertex Pharma Gyógyászati készítmények cisztás fibrózis transzmembrán konduktancia regulátor kövzetítette betegségek kezelésére
JP6578349B2 (ja) 2014-08-11 2019-09-18 アンジオン バイオメディカ コーポレーション チトクロームp450阻害剤およびその使用
US10287282B2 (en) 2014-12-31 2019-05-14 Angion Biomedica Corp. Methods and agents for treating disease
DK3283527T3 (da) 2015-04-13 2021-03-08 Five Prime Therapeutics Inc Kombinationsterapi mod cancer
IL305843B2 (en) 2015-07-20 2025-01-01 Genzyme Corp CSF-1R receptor antibodies
CA3079029A1 (en) 2017-10-13 2019-04-18 Plexxikon Inc. Solid forms of a compound for modulating kinases
GB201905721D0 (en) 2019-04-24 2019-06-05 Univ Dundee Compounds
CN113861198B (zh) * 2020-06-30 2024-08-02 上海医药集团股份有限公司 咪唑并[4,5-b]吡嗪类化合物、其制备方法及应用
JP2024500919A (ja) 2020-12-23 2024-01-10 ジェンザイム・コーポレーション 重水素化コロニー刺激因子-1受容体(csf-1r)阻害剤

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6960584B2 (en) * 2001-04-10 2005-11-01 Merck & Co., Inc. Inhibitors of Akt activity
WO2002083139A1 (en) * 2001-04-10 2002-10-24 Merck & Co., Inc. Inhibitors of akt activity
KR100932677B1 (ko) * 2001-08-10 2009-12-22 요코하마 티엘오 가부시키가이샤 열전달 장치
PT1966214T (pt) * 2005-12-21 2017-02-03 Janssen Pharmaceutica Nv Triazolpiridazinas como moduladores de tirosina quinase
JP2009538899A (ja) * 2006-05-30 2009-11-12 ファイザー・プロダクツ・インク トリアゾロピリダジン誘導体
PE20121506A1 (es) * 2006-07-14 2012-11-26 Amgen Inc Compuestos triazolopiridinas como inhibidores de c-met

Also Published As

Publication number Publication date
US8071581B2 (en) 2011-12-06
EA016527B1 (ru) 2012-05-30
JP2010507577A (ja) 2010-03-11
EP2081937A2 (en) 2009-07-29
DK2081937T3 (da) 2012-10-01
CA2667453A1 (en) 2008-05-02
KR101083177B1 (ko) 2011-11-11
EA200970402A1 (ru) 2009-10-30
MX2009004060A (es) 2009-06-19
PE20081256A1 (es) 2008-10-13
EP2081937B1 (en) 2012-09-12
WO2008051805A2 (en) 2008-05-02
WO2008051805A3 (en) 2008-07-10
US20100120739A1 (en) 2010-05-13
BRPI0717317A2 (pt) 2013-10-22
KR20090069303A (ko) 2009-06-30
PT2081937E (pt) 2012-10-15
AU2007309237A1 (en) 2008-05-02
TW200833692A (en) 2008-08-16
AU2007309237B2 (en) 2012-03-22
ES2393132T3 (es) 2012-12-18

Similar Documents

Publication Publication Date Title
PL2081937T3 (pl) Triazolopirydazynowe modulatory kinaz białkowych
SI2081937T1 (sl) Triazolopiridazinski modulatorji proteinskih kinaz
EP2259678A4 (en) PROTEIN KINASE MODULATORS
IL197958A0 (en) Bicyclic triazoles as protein kinase modulators
EP2162132A4 (en) Heterocyclic kinase modulators
IL197015A0 (en) Benzotriazole kinase modulators
IL180790A0 (en) Pyrrolo-pyridine kinase modulators
IL184657A0 (en) Adam-9 modulators
IL226486A (en) Converted pyrazolopyrimidine compounds
LT3118220T (lt) Baltymas
IL194814A0 (en) Mglur5 modulators i
GB0620934D0 (en) Protein variants
GB0611116D0 (en) Proteins
IL197722A0 (en) Mglur5 modulators
IL187692A0 (en) Alkylquinoline and alkylquinazoline kinase modulators
IL189846A0 (en) Theramutein modulators
GB0601976D0 (en) Proteins
GB0620735D0 (en) Proteins
GB0610140D0 (en) Protein stability
GB0719231D0 (en) Protein
ZA200806237B (en) Cannibinoid receptor modulators
GB0612443D0 (en) Protein
GB2463434B (en) Mitogen activated protein kinase modulator
ZA200800272B (en) Alkylquinoline and alkylquinazoline kinase modulators
GB0614682D0 (en) Proteins